期刊文献+

罗氟司特片在比格犬体内的药动学与相对生物利用度 被引量:1

Pharmacokinetics and Relative Bioavailability of Roflumilast Tablets in Beagle Dogs
暂未订购
导出
摘要 目的观察罗氟司特片在健康比格犬体内的药动学特点,比较受试制剂和参比制剂的相对生物利用度。方法健康雄性比格犬6只,随机、交叉、单剂量灌服罗氟司特片受试制剂或参比制剂500μg,采用高效液相色谱-串联质谱(HPLC-MS/MS)法测定血浆罗氟司特浓度,用DAS软件计算药动学参数,比较相对生物利用度。结果罗氟司特受试制剂和参比制剂的主要药动学参数如下:浓度-时间曲线下面积(AUC0-t)分别为(16.33±9.79),(16.21±10.43)μg·h·L-1;AUC0-∞分别为(17.11±10.39),(16.86±10.70)μg·h·L-1;峰浓度(Cmax)分别为(5.07±2.74),(5.39±3.67)μg·L-1;达峰时间(tmax)分别为(1.04±0.51),(0.96±0.56)h;半衰期(t1/2)分别为(1.97±0.65),(2.21±0.72)h。受试制剂对参比制剂的相对生物利用度为(100.9±6.3)%。结论建立的HPLC-MS/MS法适用于罗氟司特片的药动学研究,受试制剂与参比制剂的药动学特征相似。 Objective To study the pharmacokinetic characteristics of roflumilast tablets in healthy Beagle dogs and compare relative bioavailability of the test and the reference formulations. Methods Single dose of 500 μg test or reference preparations of roflumilast tablets were orally administered to 6 healthy male Beagle dogs in a randomized,cross-over study.Plasma concentrations were determined by high performance liquid chromatography-tandem mass spectrometry( HPLC-MS / MS) method.The pharmacokinetic parameters were calculated by DAS software and the relative bioavailability was compared. Results The main pharmacokinetic parameters of the test and reference roflumilast tablets were as follows: the area under the concentrationtime curve( AUC0-t) values were( 16.33±9.79) and( 16.21±10.43) μg·h·L^-1,respectively; AUC0-∞values were( 17. 11 ±10.39) and( 16.86± 10. 70) μg·h·L^-1,respectively; the peak concentration( Cmax) values were( 5.07±2.74) and( 5.39±3.67) μg·L^-1,respectively; the times to peak concerntration( tmax) were( 1.04±0.51) and( 0.96±0.56) h,respectively; the half-life( t1 / 2) values were( 1.97± 0.65) and( 2.21± 0.72) h,respectively. The relative bioavailability of the test tablets was( 100.9±6.3) % compared with the reference tablets. Conclusion The established HPLC-MS/MS method is suitable for the pharmacokinetic study of the roflumilast tablets,and the pharmacokinetic characteristics are similar between the test formulation and the reference one.
出处 《医药导报》 CAS 2016年第1期4-7,共4页 Herald of Medicine
基金 国家"重大新药创制"科技重大专项"十二五"计划(2011ZX09302-002-01)
关键词 罗氟司特 色谱-串联质谱 高效液相 药动学 生物利用度 相对 Roflumilast Chromatography-tandem mass spectrometry high performance liquid Pharmacokinetics Bioavailability relative
  • 相关文献

参考文献10

  • 1徐朝江,王卓.罗氟司特的药动学和安全性研究进展[J].医药导报,2013,32(3):321-325. 被引量:6
  • 2闫文娜,陈艳明,倪成良,郑兴.罗氟司特中有关物质的鉴定和含量测定[J].药物分析杂志,2013,33(10):1726-1730. 被引量:7
  • 3何凤琴,周磊,秦妮,罗晶,王雪根.罗氟司特主药和有关物质的HPLC法测定[J].医学美学美容(中旬刊),2013(3):155-156. 被引量:8
  • 4THEVIS M, KRUG O, SCHANZER W. Monitoring phospho- diesterase-4 inhibitors using liquid chromatography/ (tandem) mass spectrometry in sports drug testing [ J ]. Rapid Commun Mass Spectrom, 2013,27 ( 4 ) : 993-1004.
  • 5KNEBEL N G, HERZOG R, REUTTER F, et al. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2012,893- 894(1) :82-91.
  • 6THAPPALI S R,VARANASI K V,VEERARAGHAVAN S, et al. Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC- MS/MS :application for a pharmacokinetic study[ J] .J Mass Spectrom,2012,47(12) : 1612-1619.
  • 7BETHKE T D, BOHMER G M, HERMANN R, et al.Dose- proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor [ J ]. Clin Pharmacol, 2007,47 (1) :26-36.
  • 8向左娟,孙宏斌.罗氟司特N-氧化物的合成与晶型研究[J].中国药科大学学报,2012,43(6):492-496. 被引量:1
  • 9FDA. Center for drug evaluation and research [ EB/OL ]. [ 2010 - 08 - 31 ]./http://www. accessdata, fda. gov! drugsatfda docs/nda/2011/022522rig/022522rigls000- PharmR.pdf.
  • 10陈曦,马越鸣,钟杰.药物浓度-时间曲线双峰现象研究进展[J].中国新药与临床杂志,2012,31(8):432-437. 被引量:20

二级参考文献62

  • 1丁俊杰,焦正,郁韵秋,施孝金.利培酮和其主要活性代谢产物9-羟基利培酮代谢动力学模型的建立和鉴别[J].药学学报,2007,42(6):631-638. 被引量:5
  • 2GODFREY KR, ARUNDEL PA, DONG Z, et 01. Modelling the double peak phenomenon in pharmacokinetics[J]. Comput Methods Programs Biomed, 2011, 14(2): 62-69.
  • 3OKUSANYA O, FORREST A, DIFRANCESCO R, et ol. Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks[J]. Antimicrob Agents C hemother, 2007, 51 (5): 1822-1826.
  • 4MACHERAS P, ARGYRAKIS P. Gastrointestinal drug ab- sorption: is it time to consider heterogeneity as well as homogeneity?[J]. Pharma Res, 1997, 14(7) : 842-847.
  • 5ZHOU H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles[J]. J Clin Pharmacol, 2003, 43 (3): 211-227.
  • 6OBERLE RL, AMIDON GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve ofcimetidine; an explanation for the double peak phenomenon[J]. J Pharmacokinet Biooharm, 1987, 15(5) : 529-544.
  • 7MARATHE PH, SANDEFER EP, KOLLIA GE, et al. In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma seintigraphy [J]. J Phal-nacokinet Biopharm, 1998, 26(1): 1-20.
  • 8GRUNDY JS, ELIOT LA, KULMATYCKI KM, et ol. Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat[J]. Biopharm Drug Dispos, 1998, 19(3): 175-183.
  • 9SANAKA M, YAMAMOTO T, TSUTSUMI H, et al. Wagner- Nelson method for analysing the atypical double-peaked [-3CO2] exeretion curve in the [-3C]-octanoate gastric emptying breath test in humans[J]. Clin Exp Pharmacol Physiol, 2005, 32(7) : 590- 594.
  • 10CHANG RK, SHOJAE1 AH. Effeet of a lipoidic excipient on the absorption profile of compound UK81252 in dogs after oral administration[J]. J Pharm Pharm Sci, 2004, 7(1): 8-12.

共引文献32

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部